{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:20:26Z","timestamp":1777594826408,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00292-024-01385-8","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:59:10Z","timestamp":1731430750000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnblase: Tumorvorstufen und nichtinvasive Karzinome","Urinary bladder: tumor precursors and non-invasive carcinoma"],"prefix":"10.1007","volume":"46","author":[{"given":"Fabienne","family":"Lange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-3349","authenticated-orcid":false,"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"12","key":"1385_CR1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein\u00a0JI et\u00a0al (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435\u20131448","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1385_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jpedsurg.2017.11.024","volume":"53","author":"JA Saltsman","year":"2018","unstructured":"Saltsman\u00a0JA et\u00a0al (2018) Urothelial neoplasms in pediatric and young adult patients: A\u00a0large single-center series. J\u00a0Pediatr Surg 53(2):306\u2013309","journal-title":"J Pediatr Surg"},{"issue":"3","key":"1385_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7150\/jca.17482","volume":"8","author":"V Weyerer","year":"2017","unstructured":"Weyerer\u00a0V et\u00a0al (2017) Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45\u00a0years. J\u00a0Cancer 8(3):323\u2013331","journal-title":"J Cancer"},{"issue":"6","key":"1385_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00428-017-2164-5","volume":"471","author":"MDC Rodriguez Pena","year":"2017","unstructured":"Rodriguez Pena\u00a0MDC et\u00a0al (2017) Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch 471(6):761\u2013767","journal-title":"Virchows Arch"},{"key":"1385_CR5","volume-title":"Urinary and male genital tumours. Vol. WHO classification of tumours series, 5th\u00a0ed.; vol.\u00a08","author":"-","year":"2022","unstructured":"- (2022) Urinary and male genital tumours. Vol. WHO classification of tumours series, 5th\u00a0ed.; vol.\u00a08. International Agency for Research on Cancer"},{"issue":"7","key":"1385_CR6","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/PAS.0000000000001450","volume":"44","author":"TL Lotan","year":"2020","unstructured":"Lotan\u00a0TL et\u00a0al (2020) Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol 44(7):e15\u2013e29","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1385_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles\u00a0MA, Hurst\u00a0CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25\u201341","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1385_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.eururo.2009.09.022","volume":"57","author":"BW van Rhijn","year":"2010","unstructured":"van Rhijn\u00a0BW et\u00a0al (2010) The pathologist\u2019s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 57(6):1052\u20131057","journal-title":"Eur Urol"},{"issue":"3","key":"1385_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.euf.2018.01.003","volume":"5","author":"EM Comperat","year":"2019","unstructured":"Comperat\u00a0EM et\u00a0al (2019) Grading of Urothelial Carcinoma and The New \u201cWorld Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016\u201d. Eur Urol Focus 5(3):457\u2013466","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1385_CR10","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/PAS.0000000000002077","volume":"48","author":"GP Paner","year":"2024","unstructured":"Paner\u00a0GP et\u00a0al (2024) International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group\u00a02: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol 48(1):e11\u2013e23","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1385_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/path.1259","volume":"199","author":"EC Obermann","year":"2003","unstructured":"Obermann\u00a0EC et\u00a0al (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J\u00a0Pathol 199(1):50\u201357","journal-title":"J Pathol"},{"issue":"2","key":"1385_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.humpath.2009.07.002","volume":"41","author":"KB Hodges","year":"2010","unstructured":"Hodges\u00a0KB et\u00a0al (2010) Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 41(2):155\u2013162","journal-title":"Hum Pathol"},{"issue":"2","key":"1385_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/path.5250","volume":"248","author":"T Heide","year":"2019","unstructured":"Heide\u00a0T et\u00a0al (2019) Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. J\u00a0Pathol 248(2):230\u2013242","journal-title":"J Pathol"},{"issue":"2","key":"1385_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jasc.2021.12.003","volume":"11","author":"EM Wojcik","year":"2022","unstructured":"Wojcik\u00a0EM, Kurtycz\u00a0DFI, Rosenthal\u00a0DL (2022) We\u2019ll always have Paris The Paris System for Reporting Urinary Cytology 2022. J\u00a0Am Soc Cytopathol 11(2):62\u201366","journal-title":"J Am Soc Cytopathol"},{"issue":"4","key":"1385_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.urolonc.2010.04.008","volume":"28","author":"DJ McConkey","year":"2010","unstructured":"McConkey\u00a0DJ et\u00a0al (2010) Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 28(4):429\u2013440","journal-title":"Urol Oncol"},{"issue":"8","key":"1385_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","volume":"25","author":"JK McKenney","year":"2001","unstructured":"McKenney\u00a0JK et\u00a0al (2001) Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 25(8):1074\u20131078","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1385_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/PAI.0000000000000872","volume":"29","author":"KA Lombardo","year":"2021","unstructured":"Lombardo\u00a0KA et\u00a0al (2021) Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. Appl Immunohistochem Mol Morphol 29(2):127\u2013135","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1385_CR18","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/0008-5472.CAN-20-2336","volume":"81","author":"A Wullweber","year":"2021","unstructured":"Wullweber\u00a0A et\u00a0al (2021) Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling. Cancer Res 81(6):1552\u20131566","journal-title":"Cancer Res"},{"issue":"1","key":"1385_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eururo.2006.08.037","volume":"51","author":"SF Shariat","year":"2007","unstructured":"Shariat\u00a0SF et\u00a0al (2007) Concomitant carcinoma in situ is a\u00a0feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51(1):152\u2013160","journal-title":"Eur Urol"},{"key":"1385_CR20","doi-asserted-by":"crossref","unstructured":"Lange F et\u00a0al (2024) Digital volumetric assessment of CIS and tumor mass compliments conventional histopathological assessment in muscle-invasive urothelial bladder cancer. Virchows Arch","DOI":"10.1007\/s00428-024-03875-9"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-024-01385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-024-01385-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-024-01385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:41:29Z","timestamp":1738255289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-024-01385-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1007\/s00292-024-01385-8","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"8 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Lange gibt an, dass kein Interessenkonflikt besteht. A.\u00a0Hartmann: Honorare von Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, 3DHistotech; Beratungsgeb\u00fchren von Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech; Forschungsf\u00f6rderung von AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche. M.\u00a0Eckstein: Honorare und Reisekosten von MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS; Forschungsf\u00f6rderung von AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH; Beratungsgeb\u00fchren von Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}